Drug profile

The FDA adverse-event record for Dimenhydrinate

15 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Dimenhydrinate. See the species affected, top reactions, and outcomes below.

15
adverse-event reports
0.0%
death-coded share
Dog
most-reported species
4
Behavioural disorder NOS - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
15
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

Dimenhydrinate

Administration Routes

UnknownOral

Species Affected

Dog 14
Cat 1

Most Affected Breeds

Crossbred Canine/dog 4
Retriever - Labrador 3
Cattle Dog - Australian (blue heeler, red heeler, Queensland cattledog) 2
Shepherd Dog - German 2
Shih Tzu 1
Papillon - Spaniel - Continental Toy (with erect ears or with dropped ears (Phaléne)) 1
Domestic Shorthair 1
Beagle 1

Most Reported Reactions

Behavioural disorder NOS 4
Lack of efficacy - NOS 4
Ataxia 4
Vestibular disorder NOS 4
Not eating 4
Nystagmus 4
Emesis 3
Polydipsia 3
Tympanic rupture 3
Diarrhoea 3
Head tilt - neurological disorder (see also Head tilt - ear disorder) 3
Lethargy (see also Central nervous system depression in 'Neurological') 2

Outcome Breakdown

Ongoing
5 (33.3%)
Recovered/Normal
5 (33.3%)
Outcome Unknown
4 (26.7%)
Recovered with Sequela
1 (6.7%)

Dimenhydrinate Adverse Event Insights

15 reports name Dimenhydrinate; 0 recorded a death outcome (0.0% of reported events, not a population-level mortality rate). Active ingredient: Dimenhydrinate. Administration routes: Unknown, Oral.

By species: Dog (14 reports), Cat (1 reports). By breed: Crossbred Canine/dog (4), Retriever - Labrador (3), Cattle Dog - Australian (blue heeler, red heeler, Queensland cattledog) (2).

Leading clinical signs: Behavioural disorder NOS (4), Lack of efficacy - NOS (4), Ataxia (4), Vestibular disorder NOS (4). Outcome, 15 coded reports: Ongoing leads at 33.3%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.